268 related articles for article (PubMed ID: 20922572)
21. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
22. Natural immunity to cancer in humans.
Bindea G; Mlecnik B; Fridman WH; Pagès F; Galon J
Curr Opin Immunol; 2010 Apr; 22(2):215-22. PubMed ID: 20207124
[TBL] [Abstract][Full Text] [Related]
23. [Tumor-induced immunosuppression].
Paul S; Calmels B; Régulier E
Ann Biol Clin (Paris); 2002; 60(2):143-52. PubMed ID: 11937439
[TBL] [Abstract][Full Text] [Related]
24. CD40-induced countercurrent conduits for tumor escape or elimination?
Murugaiyan G; Martin S; Saha B
Trends Immunol; 2007 Nov; 28(11):467-73. PubMed ID: 17981086
[TBL] [Abstract][Full Text] [Related]
25. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy?
Apte RN; Voronov E
Immunol Rev; 2008 Apr; 222():222-41. PubMed ID: 18364005
[TBL] [Abstract][Full Text] [Related]
26. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
27. Harnessing the immune response to treat cancer.
Steer HJ; Lake RA; Nowak AK; Robinson BW
Oncogene; 2010 Dec; 29(48):6301-13. PubMed ID: 20856204
[TBL] [Abstract][Full Text] [Related]
28. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
[TBL] [Abstract][Full Text] [Related]
29. Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention.
Bronte V; Cingarlini S; Marigo I; De Santo C; Gallina G; Dolcetti L; Ugel S; Peranzoni E; Mandruzzato S; Zanovello P
Immunol Invest; 2006; 35(3-4):327-57. PubMed ID: 16916757
[TBL] [Abstract][Full Text] [Related]
30. From cancer immunosurveillance to cancer immunotherapy.
Stagg J; Johnstone RW; Smyth MJ
Immunol Rev; 2007 Dec; 220():82-101. PubMed ID: 17979841
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapies to improve tumor immunotherapy.
Begley J; Ribas A
Clin Cancer Res; 2008 Jul; 14(14):4385-91. PubMed ID: 18628452
[TBL] [Abstract][Full Text] [Related]
32. The dual effects of interleukin-18 in tumor progression.
Park S; Cheon S; Cho D
Cell Mol Immunol; 2007 Oct; 4(5):329-35. PubMed ID: 17976312
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulation in cancer.
Hegmans JP; Aerts JG
Curr Opin Pharmacol; 2014 Aug; 17():17-21. PubMed ID: 25011112
[TBL] [Abstract][Full Text] [Related]
34. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer.
Clark CE; Beatty GL; Vonderheide RH
Cancer Lett; 2009 Jun; 279(1):1-7. PubMed ID: 19013709
[TBL] [Abstract][Full Text] [Related]
35. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
36. Myeloid-derived suppressor cell role in tumor-related inflammation.
Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V
Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992
[TBL] [Abstract][Full Text] [Related]
37. The immune system--is it relevant to cancer development, progression and treatment?
Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):101-12. PubMed ID: 18037277
[TBL] [Abstract][Full Text] [Related]
38. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.
Allavena P; Sica A; Garlanda C; Mantovani A
Immunol Rev; 2008 Apr; 222():155-61. PubMed ID: 18364000
[TBL] [Abstract][Full Text] [Related]
39. [Molecular bases of cancer immunology].
Barrera-Rodríguez R; Peralta-Zaragoza O; Madrid-Marina V
Salud Publica Mex; 1995; 37(4):344-53. PubMed ID: 7502157
[TBL] [Abstract][Full Text] [Related]
40. The use of FoxP3 as a biomarker and prognostic factor for malignant human tumors.
Schreiber TH
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):1931-4. PubMed ID: 17932340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
